Regulatory News
Monday, January 30, 2017
BRIEF-Allergan says FDA approves sNDA for Avycaz to include Phase III data in patients with cUTI
* FDA approves sNDA for Avycaz to include new Phase III data
in patients with complicated urinary tract infections, including
pyelonephritis
Further company coverage:
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment